536 related articles for article (PubMed ID: 18958156)
41. The cancer stem cell marker CD133 has high prognostic impact but unknown functional relevance for the metastasis of human colon cancer.
Horst D; Scheel SK; Liebmann S; Neumann J; Maatz S; Kirchner T; Jung A
J Pathol; 2009 Dec; 219(4):427-34. PubMed ID: 19621338
[TBL] [Abstract][Full Text] [Related]
42. Minnelide effectively eliminates CD133(+) side population in pancreatic cancer.
Nomura A; McGinn O; Dudeja V; Sangwan V; Saluja AK; Banerjee S
Mol Cancer; 2015 Nov; 14():200. PubMed ID: 26597727
[TBL] [Abstract][Full Text] [Related]
43. Polarized cell migration induces cancer type-specific CD133/integrin/Src/Akt/GSK3β/β-catenin signaling required for maintenance of cancer stem cell properties.
Su YJ; Lin WH; Chang YW; Wei KC; Liang CL; Chen SC; Lee JL
Oncotarget; 2015 Nov; 6(35):38029-45. PubMed ID: 26515729
[TBL] [Abstract][Full Text] [Related]
44. Flow cytometric characterization of the DAOY medulloblastoma cell line for the cancer stem-like phenotype.
Srivastava VK; Nalbantoglu J
Cytometry A; 2008 Oct; 73(10):940-8. PubMed ID: 18773455
[TBL] [Abstract][Full Text] [Related]
45. Doxorubicin fails to eradicate cancer stem cells derived from anaplastic thyroid carcinoma cells: characterization of resistant cells.
Zheng X; Cui D; Xu S; Brabant G; Derwahl M
Int J Oncol; 2010 Aug; 37(2):307-15. PubMed ID: 20596658
[TBL] [Abstract][Full Text] [Related]
46. The role of CD133 in the identification and characterisation of tumour-initiating cells in non-small-cell lung cancer.
Tirino V; Camerlingo R; Franco R; Malanga D; La Rocca A; Viglietto G; Rocco G; Pirozzi G
Eur J Cardiothorac Surg; 2009 Sep; 36(3):446-53. PubMed ID: 19464919
[TBL] [Abstract][Full Text] [Related]
47. How powerful is CD133 as a cancer stem cell marker in brain tumors?
Cheng JX; Liu BL; Zhang X
Cancer Treat Rev; 2009 Aug; 35(5):403-8. PubMed ID: 19369008
[TBL] [Abstract][Full Text] [Related]
48. CD133 and CD44 cell surface markers do not identify cancer stem cells in primary human gastric tumors.
Rocco A; Liguori E; Pirozzi G; Tirino V; Compare D; Franco R; Tatangelo F; Palaia R; D'Armiento FP; Pollastrone G; Affuso A; Bottazzi EC; Masone S; Persico G; Nardone G
J Cell Physiol; 2012 Jun; 227(6):2686-93. PubMed ID: 21898409
[TBL] [Abstract][Full Text] [Related]
49. CXC chemokine receptor 4 expression and function in human anaplastic thyroid cancer cells.
Hwang JH; Hwang JH; Chung HK; Kim DW; Hwang ES; Suh JM; Kim H; You KH; Kwon OY; Ro HK; Jo DY; Shong M
J Clin Endocrinol Metab; 2003 Jan; 88(1):408-16. PubMed ID: 12519884
[TBL] [Abstract][Full Text] [Related]
50. Expression of stem-cell markers OCT-4 and CD133: important prognostic factors in papillary renal cell carcinoma.
Kim K; Ro JY; Kim S; Cho YM
Hum Pathol; 2012 Dec; 43(12):2109-16. PubMed ID: 22944295
[TBL] [Abstract][Full Text] [Related]
51. Hypoxia promotes stem-like properties of laryngeal cancer cell lines by increasing the CD133+ stem cell fraction.
Wu CP; Du HD; Gong HL; Li DW; Tao L; Tian J; Zhou L
Int J Oncol; 2014 May; 44(5):1652-60. PubMed ID: 24573690
[TBL] [Abstract][Full Text] [Related]
52. Expression of CD133 in synovial sarcoma.
Terry J; Nielsen T
Appl Immunohistochem Mol Morphol; 2010 Mar; 18(2):159-65. PubMed ID: 19752721
[TBL] [Abstract][Full Text] [Related]
53. Targeting CD133 antigen in cancer.
Ferrandina G; Petrillo M; Bonanno G; Scambia G
Expert Opin Ther Targets; 2009 Jul; 13(7):823-37. PubMed ID: 19530986
[TBL] [Abstract][Full Text] [Related]
54. Isolation, characterization and mobilization of prostate cancer tissue derived CD133+ MDR1+ cells.
Rentala S; Mangamoori LN
J Stem Cells; 2010; 5(2):75-81. PubMed ID: 22049617
[TBL] [Abstract][Full Text] [Related]
55. Physiologic oxygen concentration enhances the stem-like properties of CD133+ human glioblastoma cells in vitro.
McCord AM; Jamal M; Shankavaram UT; Lang FF; Camphausen K; Tofilon PJ
Mol Cancer Res; 2009 Apr; 7(4):489-97. PubMed ID: 19372578
[TBL] [Abstract][Full Text] [Related]
56. Biological significance of tumor budding at the invasive front of human colorectal carcinoma cells.
Yusra ; Semba S; Yokozaki H
Int J Oncol; 2012 Jul; 41(1):201-10. PubMed ID: 22569829
[TBL] [Abstract][Full Text] [Related]
57. A rational approach for cancer stem-like cell isolation and characterization using CD44 and prominin-1(CD133) as selection markers.
Lee YJ; Wu CC; Li JW; Ou CC; Hsu SC; Tseng HH; Kao MC; Liu JY
Oncotarget; 2016 Nov; 7(48):78499-78515. PubMed ID: 27655682
[TBL] [Abstract][Full Text] [Related]
58. Expression of putative stem marker nestin and CD133 in advanced serous ovarian cancer.
Qin Q; Sun Y; Fei M; Zhang J; Jia Y; Gu M; Xia R; Chen S; Deng A
Neoplasma; 2012; 59(3):310-5. PubMed ID: 22296500
[TBL] [Abstract][Full Text] [Related]
59. CD133 and CD44 are universally overexpressed in GIST and do not represent cancer stem cell markers.
Chen J; Guo T; Zhang L; Qin LX; Singer S; Maki RG; Taguchi T; Dematteo R; Besmer P; Antonescu CR
Genes Chromosomes Cancer; 2012 Feb; 51(2):186-95. PubMed ID: 22076958
[TBL] [Abstract][Full Text] [Related]
60. Non-small cell lung cancer cells expressing CD44 are enriched for stem cell-like properties.
Leung EL; Fiscus RR; Tung JW; Tin VP; Cheng LC; Sihoe AD; Fink LM; Ma Y; Wong MP
PLoS One; 2010 Nov; 5(11):e14062. PubMed ID: 21124918
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]